<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Citalopram</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00215</strong>&#160; (APRD00147)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>Citalopram hydrobromide belongs to a class of antidepressant agents known as selective serotonin-reuptake inhibitors (SSRIs). Citalopram and its N-demethylated metabolites exist as a racemic mixture but its effects are largely due to the S-enantiomer, S-citalopram and S-demthylcitalopram. Despite distinct structural differences between compounds in this class, SSRIs possess similar pharmacological activity. As with other antidepressant agents, several weeks of therapy may be required before a clinical effect is seen. SSRIs are potent inhibitors of neuronal serotonin reuptake. They have little to no effect on norepinephrine or dopamine reuptake and do not antagonize &#945;- or &#946;-adrenergic, dopamine D<sub>2</sub> or histamine H<sub>1</sub> receptors. During acute use, SSRIs block serotonin reuptake and increase serotonin stimulation of somatodendritic 5-HT<sub>1A</sub> and terminal autoreceptors. Chronic use leads to desensitization of somatodendritic 5-HT<sub>1A</sub> and terminal autoreceptors. The overall clinical effect of increased mood and decreased anxiety is thought to be due to adaptive changes in neuronal function that leads to enhanced serotonergic neurotransmission. Side effects include dry mouth, nausea, dizziness, drowsiness, sexual dysfunction and headache. Side effects generally occur within the first two weeks of therapy and are usually less severe and frequent than those observed with tricyclic antidepressants. Citalopram is approved for treatment of depression. Unlabeled indications include mild dementia-associated agitation in nonpsychotic patients, smoking cessation, ethanol abuse, obsessive-compulsive disorder (<span class="caps">OCD</span>) in children, and diabetic neuropathy. Citalopram has the fewest drug-drug interactions of the SSRIs.</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00215/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00215/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00215.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00215.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00215.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00215.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00215.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00215">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>Nitalapram </td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Salts</th><td class="table-container"><table class="inner">
  <thead>
    <tr>
      <th>Name/CAS</th>
      <th>Structure</th>
      <th>Properties</th>
      <th></th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>
          <strong>Citalopram Hydrobromide</strong>
          <div class="cas">59729-32-7</div>
        </td>
        <td><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DBSALT000027/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DBSALT000027/thumb.png"></a></td>
        <td>
            <ul>
              <li>InChI Key: WIHMBLDNRMIGDW-UHFFFAOYNA-N</li>
              <li>Monoisotopic Mass: 404.089954188</li>
              <li>Average Mass: 405.304</li>
            </ul>
        </td>
        <td><a class="btn btn-default btn-xs" href="/salts/DBSALT000027">DBSALT000027</a></td>
      </tr>
  </tbody>
</table></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Akarin</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Celapram</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Celexa</td><td>Forest Laboratories</td></tr><tr><td>Ciazil</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Cilift</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Cipram</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Cipramil</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Ciprapine</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Citabax</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Citalec</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Citol</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Citopam</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Citox</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Citrol</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Dalsan</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Elopram</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Humorup</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Oropram</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Pramcit</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Recital</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Seropram</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Talam</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Talohexal</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Temperax</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Vodelax</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Zentius</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Zetalo</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/antidepressive-agents-second-generation">Antidepressive Agents, Second-Generation</a></li>
<li><a href="/mesh/serotonin-uptake-inhibitors">Serotonin Uptake Inhibitors</a></li>
<li><a href="/mesh/antidepressive-agents">Antidepressive Agents</a></li></ul></td></tr><tr><th>CAS number</th><td>59729-33-8</td></tr><tr><th>Weight</th><td>Average: 324.3919<br>Monoisotopic: 324.163791509</td></tr><tr><th>Chemical Formula</th><td>C<sub>20</sub>H<sub>21</sub>FN<sub>2</sub>O</td></tr><tr><th>InChI Key</th><td>WSEQXVZVJXJVFP-UHFFFAOYSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C20H21FN2O/c1-23(2)11-3-10-20(17-5-7-18(21)8-6-17)19-9-4-15(13-22)12-16(19)14-24-20/h4-9,12H,3,10-11,14H2,1-2H3</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile</div></td></tr><tr><th>SMILES</th><td><div class="wrap">CN(C)CCCC1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Heterocyclic Compounds</td></tr><tr><th>Class</th><td>Benzofurans</td></tr><tr><th>Subclass</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Direct parent</th><td>Benzofurans</td></tr><tr><th>Alternative parents</th><td>Benzonitriles; Fluorobenzenes; Aryl Fluorides; Tertiary Amines; Nitriles; Polyamines; Dialkyl Ethers; Organofluorides</td></tr><tr><th>Substituents</th><td>benzonitrile; fluorobenzene; aryl halide; benzene; aryl fluoride; tertiary amine; carbonitrile; ether; nitrile; polyamine; dialkyl ether; organohalogen; organofluoride; amine; organonitrogen compound</td></tr><tr><th>Classification description</th><td>This compound belongs to the benzofurans. These are organic compounds containing a benzene ring fused to a furan.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For the treatment of depression. Unlabeled indications include: treatment of mild dementia-associated agitation in nonpsychotic patients, smoking cessation, ethanol abuse, obsessive-compulsive disorder (OCD) in children, and diabetic neuropathy. </td></tr><tr><th>Pharmacodynamics</th><td>Citalopram is one of a class of antidepressants known as selective serotonin reuptake inhibitors (SSRIs). It is used to treat the depression associated with mood disorders. It is also used on occassion in the treatment of body dysmorphic disorder and anxiety. The antidepressant, antiobsessive-compulsive, and antibulimic actions of citalopram are presumed to be linked to its inhibition of CNS neuronal uptake of serotonin. <i>In vitro</i> studies show that citalopram is a potent and selective inhibitor of neuronal serotonin reuptake and has only very weak effects on norepinephrine and dopamine neuronal reuptake. Citalopram has no significant affinity for adrenergic (&#945;<sub>1</sub>, &#945;<sub>2</sub>, &#946;), cholinergic, GABA, dopaminergic, histaminergic, serotonergic (5HT<sub>1A</sub>, 5HT<sub>1B</sub>, 5HT<sub>2</sub>), or benzodiazepine receptors; antagonism of such receptors has been hypothesized to be associated with various anticholinergic, sedative, and cardiovascular effects for other psychotropic drugs. The chronic administration of citalopram was found to downregulate brain norepinephrine receptors, as has been observed with other drugs effective in the treatment of major depressive disorder. Citalopram does not inhibit monoamine oxidase.</td></tr><tr><th>Mechanism of action</th><td>The antidepressant, antiobsessive-compulsive, and antibulimic actions of citalopram are presumed to be linked to its inhibition of CNS neuronal uptake of serotonin. Citalopram blocks the reuptake of serotonin at the serotonin reuptake pump of the neuronal membrane, enhancing the actions of serotonin on 5HT<sub>1A</sub> autoreceptors. SSRIs bind with significantly less affinity to histamine, acetylcholine, and norepinephrine receptors than tricyclic antidepressant drugs.</td></tr><tr><th>Absorption</th><td>Rapidly and well absorbed from the GI tract. Peak plasma concentrations occur within 4 hours of a single orally administered dose. Bioavailability is 80% following oral administration. Food does not affect absorption. </td></tr><tr><th>Volume of distribution</th><td><ul>
	<li>12 L/kg<br>
Citalopram is highly lipophilic and likely widely distributed throughout the body, including the blood-brain-barrier. However, its metabolite, demethylcitalopram does not cross the barrier well.</li>
</ul></td></tr><tr><th>Protein binding</th><td>Citalopram, dimethylcitalopram, and didemethylcitalopram is 80% bound to plasma proteins. </td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Citalopram is metabolized mainly in the liver via <i>N</i>-demethylation to its principle metabolite, demethylcitalopram. Other metabolites include didemethylcitalopram, citalopram <i>N</i>-oxide, and a deaminated propionic acid derivative. However, the predominant entity in plasma is unchanged citalopram. Cytochrome P450 (CYP) 3A4 and 2C19 isozymes appear to be principally involved in producing demethylcitalopram. Demethylcitalopram appears to be further <i>N</i>-demethylated by CYP2D6 to didemethylcitalopram. Citalopram metabolites possess little pharmacologic activity in comparison to their parent compound and do not likely contribute to the clinical effect of the drug. </p><table class="table-standard table-condensed" id="experimental-properties"><thead><tr><th>Substrate</th><th>Enzymes</th><th colspan="2">Product</th></tr></thead><tbody><tr><td>Citalopram</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002363" target="_blank">Cytochrome P450 2D6</a></li></ul></td><td><a href="/metabolites/DBMET00195">Citalopram <i>N</i>-oxide</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/196">Details</a></td></tr><tr><td>Citalopram</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002363" target="_blank">Cytochrome P450 2D6</a></li>
<li><a href="/biodb/bio_entities/BE0003536" target="_blank">Cytochrome P450 2C19</a></li>
<li><a href="/biodb/bio_entities/BE0002638" target="_blank">Cytochrome P450 3A4</a></li></ul></td><td><a href="/metabolites/DBMET00196"><i>N</i>-Desmethylcitalopram</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/197">Details</a></td></tr><tr><td>Citalopram</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET00659">Citalopram propionic acid</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/680">Details</a></td></tr><tr><td><a href="/metabolites/DBMET00196"><i>N</i>-Desmethylcitalopram</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002363" target="_blank">Cytochrome P450 2D6</a></li></ul></td><td><a href="/metabolites/DBMET00661"><i>N,N</i>-Didesmethylcitalopram</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1148">Details</a></td></tr></tbody></table></td></tr><tr><th>Route of elimination</th><td>12-23% of an oral dose of citalopram is recovered unchanged in the urine, while 10% of the dose is recovered in the feces. </td></tr><tr><th>Half life</th><td>35 hours</td></tr><tr><th>Clearance</th><td><p>The systemic clearance of citalopram was 330 mL/min, with approximately 20% of that due to renal clearance.</p></td></tr><tr><th>Toxicity</th><td>Symptoms most often accompanying citalopram overdose, alone or in combination with other drugs and/or alcohol, included dizziness, sweating, nausea, vomiting, tremor, somnolence, and sinus tachycardia. In more rare cases, observed symptoms included amnesia, confusion, coma, convulsions, hyperventilation, cyanosis, rhabdomyolysis, and ECG changes (including QTc prolongation, nodal rhythm, ventricular arrhythmia, and very rare cases of torsade de pointes). Acute renal failure has been very rarely reported accompanying overdose. Withdrawal symptoms include flu-like symptoms, insomnia, nausea, imbalance, sensory changes and hyperactivity. </td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="snp-fx"><thead><tr><th>Interacting Gene/Enzyme</th><th>SNP RS ID</th><th>Allele name</th><th>Defining change</th><th>Effect</th><th>Reference(s)</th></tr></thead><tbody><tr><td>Multidrug resistance protein 1<br>Gene symbol: ABCB1<br>UniProt: <a class="wishart-link-out" href="http://www.uniprot.org/uniprot/P08183" target="_blank">P08183 <span class="glyphicon glyphicon-new-window"> </span></a></td><td><a class="wishart-link-out" href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=rs2032583" target="_blank">rs2032583 <span class="glyphicon glyphicon-new-window"> </span></a></td><td><span class="wishart wishart-not-available">Not Available</span></td><td>C Allele</td><td>Improved response to antidepressant medication</td><td><span class="citation"><a class="pubmed-link wishart-link-out" data-toggle="tooltip" href="http://www.ncbi.nlm.nih.gov/pubmed/17913323" target="_blank" title="Uhr M, Tontsch A, Namendorf C, Ripke S, Lucae S, Ising M, Dose T, Ebinger M, Rosenhagen M, Kohli M, Kloiber S, Salyakina D, Bettecken T, Specht M, Putz B, Binder EB, Muller-Myhsok B, Holsboer F: Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression. Neuron. 2008 Jan 24;57(2):203-9. [18215618 ]
    Kato M, Fukuda T, Serretti A, Wakeno M, Okugawa G, Ikenaga Y, Hosoi Y, Takekita Y, Mandelli L, Azuma J, Kinoshita T: ABCB1 (MDR1) gene polymorphisms are associated with the clinical response to paroxetine in patients with major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2008 Feb 15;32(2):398-404. Epub 2007 Sep 15.">17913323 <span class="glyphicon glyphicon-new-window"> </span></a></span></td></tr><tr><td>5-hydroxytryptamine receptor 2A<br>Gene symbol: HTR2A<br>UniProt: <a class="wishart-link-out" href="http://www.uniprot.org/uniprot/P28223" target="_blank">P28223 <span class="glyphicon glyphicon-new-window"> </span></a></td><td><a class="wishart-link-out" href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=rs7997012" target="_blank">rs7997012 <span class="glyphicon glyphicon-new-window"> </span></a></td><td><span class="wishart wishart-not-available">Not Available</span></td><td>A Allele</td><td>Improved response to antidepressant medication</td><td><span class="citation"><a class="pubmed-link wishart-link-out" data-toggle="tooltip" href="http://www.ncbi.nlm.nih.gov/pubmed/16642436" target="_blank" title="McMahon FJ, Buervenich S, Charney D, Lipsky R, Rush AJ, Wilson AF, Sorant AJ, Papanicolaou GJ, Laje G, Fava M, Trivedi MH, Wisniewski SR, Manji H: Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment. Am J Hum Genet. 2006 May;78(5):804-14. Epub 2006 Mar 20.">16642436 <span class="glyphicon glyphicon-new-window"> </span></a></span></td></tr><tr><td>Glutamate receptor ionotropic, kainate 4<br>Gene symbol: GRIK4<br>UniProt: <a class="wishart-link-out" href="http://www.uniprot.org/uniprot/Q16099" target="_blank">Q16099 <span class="glyphicon glyphicon-new-window"> </span></a></td><td><a class="wishart-link-out" href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=rs1954787" target="_blank">rs1954787 <span class="glyphicon glyphicon-new-window"> </span></a></td><td><span class="wishart wishart-not-available">Not Available</span></td><td>C Allele</td><td>Improved response to antidepressant medication</td><td><span class="citation"><a class="pubmed-link wishart-link-out" data-toggle="tooltip" href="http://www.ncbi.nlm.nih.gov/pubmed/17671280" target="_blank" title="Paddock S, Laje G, Charney D, Rush AJ, Wilson AF, Sorant AJ, Lipsky R, Wisniewski SR, Manji H, McMahon FJ: Association of GRIK4 with outcome of antidepressant treatment in the STAR*D cohort. Am J Psychiatry. 2007 Aug;164(8):1181-8.">17671280 <span class="glyphicon glyphicon-new-window"> </span></a></span></td></tr><tr><td>5-hydroxytryptamine receptor 1A<br>Gene symbol: HTR1A<br>UniProt: <a class="wishart-link-out" href="http://www.uniprot.org/uniprot/P08908" target="_blank">P08908 <span class="glyphicon glyphicon-new-window"> </span></a></td><td><a class="wishart-link-out" href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=rs6295" target="_blank">rs6295 <span class="glyphicon glyphicon-new-window"> </span></a></td><td><span class="wishart wishart-not-available">Not Available</span></td><td>G Allele</td><td>Homozygosity for the rs6295 G allele is associated with lower response rate in patients treated for major depression</td><td><span class="citation"><a class="pubmed-link wishart-link-out" data-toggle="tooltip" href="http://www.ncbi.nlm.nih.gov/pubmed/19829169" target="_blank" title='# Villafuerte SM, Vallabhaneni K, Sliwerska E, McMahon FJ, Young EA, Burmeister M: SSRI response in depression may be influenced by SNPs in HTR1B and HTR1A. Psychiatr Genet. 2009 Dec;19(6):281-91. doi: 10.1097/YPG.0b013e32832a506e. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/19829169'>19829169 <span class="glyphicon glyphicon-new-window"> </span></a></span></td></tr></tbody></table></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="snp-fx"><thead><tr><th>Interacting Gene/Enzyme</th><th>SNP RS ID</th><th>Allele name</th><th>Defining change</th><th>Adverse Reaction</th><th>Reference(s)</th></tr></thead><tbody><tr><td>Glutamate receptor ionotropic, kainate 2<br>Gene symbol: GRIK2<br>UniProt: <a class="wishart-link-out" href="http://www.uniprot.org/uniprot/Q13002" target="_blank">Q13002 <span class="glyphicon glyphicon-new-window"> </span></a></td><td><a class="wishart-link-out" href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=rs2518224" target="_blank">rs2518224 <span class="glyphicon glyphicon-new-window"> </span></a></td><td><span class="wishart wishart-not-available">Not Available</span></td><td>C Allele, homozygote</td><td>Increased suicidal thoughts</td><td><span class="citation"><a class="pubmed-link wishart-link-out" data-toggle="tooltip" href="http://www.ncbi.nlm.nih.gov/pubmed/17898344" target="_blank" title="Laje G, Paddock S, Manji H, Rush AJ, Wilson AF, Charney D, McMahon FJ: Genetic markers of suicidal ideation emerging during citalopram treatment of major depression. Am J Psychiatry. 2007 Oct;164(10):1530-8.">17898344 <span class="glyphicon glyphicon-new-window"> </span></a></span></td></tr><tr><td>Glutamate receptor 3<br>Gene symbol: GRIA3<br>UniProt: <a class="wishart-link-out" href="http://www.uniprot.org/uniprot/P42263" target="_blank">P42263 <span class="glyphicon glyphicon-new-window"> </span></a></td><td><a class="wishart-link-out" href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=rs4825476" target="_blank">rs4825476 <span class="glyphicon glyphicon-new-window"> </span></a></td><td><span class="wishart wishart-not-available">Not Available</span></td><td>G Allele, homozygote</td><td>Increased suicidal thoughts</td><td><span class="citation"><a class="pubmed-link wishart-link-out" data-toggle="tooltip" href="http://www.ncbi.nlm.nih.gov/pubmed/17898344" target="_blank" title="Laje G, Paddock S, Manji H, Rush AJ, Wilson AF, Charney D, McMahon FJ: Genetic markers of suicidal ideation emerging during citalopram treatment of major depression. Am J Psychiatry. 2007 Oct;164(10):1530-8.">17898344 <span class="glyphicon glyphicon-new-window"> </span></a></span></td></tr><tr><td>Cyclic AMP-responsive element-binding protein 1<br>Gene symbol: CREB1<br>UniProt: <a class="wishart-link-out" href="http://www.uniprot.org/uniprot/P16220" target="_blank">P16220 <span class="glyphicon glyphicon-new-window"> </span></a></td><td><a class="wishart-link-out" href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=rs4675690" target="_blank">rs4675690 <span class="glyphicon glyphicon-new-window"> </span></a></td><td><span class="wishart wishart-not-available">Not Available</span></td><td>T Allele</td><td>Elevated suicide risk</td><td><span class="citation"><a class="pubmed-link wishart-link-out" data-toggle="tooltip" href="http://www.ncbi.nlm.nih.gov/pubmed/17548750" target="_blank" title="Perlis RH, Purcell S, Fava M, Fagerness J, Rush AJ, Trivedi MH, Smoller JW: Association between treatment-emergent suicidal ideation with citalopram and polymorphisms near cyclic adenosine monophosphate response element binding protein in the STAR*D study. Arch Gen Psychiatry. 2007 Jun;64(6):689-97.">17548750 <span class="glyphicon glyphicon-new-window"> </span></a></span></td></tr><tr><td>Cyclic AMP-responsive element-binding protein 1<br>Gene symbol: CREB1<br>UniProt: <a class="wishart-link-out" href="http://www.uniprot.org/uniprot/P16220" target="_blank">P16220 <span class="glyphicon glyphicon-new-window"> </span></a></td><td><a class="wishart-link-out" href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=rs7569963" target="_blank">rs7569963 <span class="glyphicon glyphicon-new-window"> </span></a></td><td><span class="wishart wishart-not-available">Not Available</span></td><td>A Allele</td><td>Elevated suicide risk</td><td><span class="citation"><a class="pubmed-link wishart-link-out" data-toggle="tooltip" href="http://www.ncbi.nlm.nih.gov/pubmed/17548750" target="_blank" title="Perlis RH, Purcell S, Fava M, Fagerness J, Rush AJ, Trivedi MH, Smoller JW: Association between treatment-emergent suicidal ideation with citalopram and polymorphisms near cyclic adenosine monophosphate response element binding protein in the STAR*D study. Arch Gen Psychiatry. 2007 Jun;64(6):689-97.">17548750 <span class="glyphicon glyphicon-new-window"> </span></a></span></td></tr></tbody></table></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.9966</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.9729</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              +
        </td>
        <td>0.6099</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.7597</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.6361</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Inhibitor
        </td>
        <td>0.9789</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Inhibitor
        </td>
        <td>0.6993</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.8401</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Substrate</td>
        <td>0.8919</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Substrate</td>
        <td>0.7407</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9045</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Inhibitor</td>
        <td>0.8949</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.5054</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Inhibitor</td>
        <td>0.8994</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8309</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>High CYP Inhibitory Promiscuity</td>
        <td>0.5223</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.7602
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.7452
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            1.0
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.9054 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.7735
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Inhibitor 
        </td>
        <td>
            0.8994
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Alphapharm party ltd</li>
<li>Forest laboratories inc</li>
<li>Apotex inc richmond hill</li>
<li>Aurobindo pharma ltd inc</li>
<li>Roxane laboratories inc</li>
<li>Silarx pharmaceuticals inc</li>
<li>Biovail laboratories international srl</li>
<li>Actavis elizabeth llc</li>
<li>Amneal pharmaceuticals ny llc</li>
<li>Apotex inc etobicoke site</li>
<li>Aurobindo pharma ltd</li>
<li>Caraco pharmaceutical laboratories ltd</li>
<li>Corepharma llc</li>
<li>Dr reddys laboratories ltd</li>
<li>Epic pharma llc</li>
<li>Glenmark generics ltd</li>
<li>Invagen pharmaceuticals inc</li>
<li>Ivax pharmaceuticals inc sub teva pharmaceuticals usa</li>
<li>Matrix laboratories inc</li>
<li>Mutual pharmaceutical co inc</li>
<li>Mylan pharmaceuticals inc</li>
<li>Natco pharma ltd</li>
<li>Pliva inc</li>
<li>Sandoz inc</li>
<li>Taro pharmaceuticals usa inc</li>
<li>Teva pharmaceuticals usa</li>
<li>Torrent pharmaceuticals ltd</li>
<li>Watson laboratories inc</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.actavis.com">Actavis Group</a></li>
<li>Advanced Pharmaceutical Services Inc.</li>
<li><a href="http://www.aidarex.com">Aidarex Pharmacuticals LLC</a></li>
<li><a href="http://www.amerisourcebergen.com">Amerisource Health Services Corp.</a></li>
<li>Amkas Laboratories Inc.</li>
<li><a href="http://www.amneal.com">Amneal Pharmaceuticals</a></li>
<li><a href="http://www.apotex.com">Apotex Inc.</a></li>
<li><a href="http://orders.a-smeds.com">A-S Medication Solutions LLC</a></li>
<li><a href="http://www.atlanticbiologicals.com">Atlantic Biologicals Corporation</a></li>
<li><a href="http://www.aurobindo.com">Aurobindo Pharma Ltd.</a></li>
<li>Aurolife Pharma LLC</li>
<li><a href="http://www.blurx.us">Blu Pharmaceuticals LLC</a></li>
<li><a href="http://bryantranchprepack.com">Bryant Ranch Prepack</a></li>
<li><a href="http://www.camberpharma.com">Camber Pharmaceuticals Inc.</a></li>
<li><a href="http://www.caraco.com">Caraco Pharmaceutical Labs</a></li>
<li><a href="http://www.cardinal.com">Cardinal Health</a></li>
<li><a href="http://www.cipla.com">Cipla Ltd.</a></li>
<li><a href="http://www.cobaltpharma.com">Cobalt Pharmaceuticals Inc.</a></li>
<li>Comprehensive Consultant Services Inc.</li>
<li><a href="http://www.corepharma.com">Corepharma LLC</a></li>
<li>Coupler Enterprises Inc.</li>
<li><a href="http://www.cypressrx.com">Cypress Pharmaceutical Inc.</a></li>
<li>Dept Health Central Pharmacy</li>
<li><a href="http://www.drxdispensing.com">Dispensing Solutions</a></li>
<li><a href="http://www.dhscorp.com">Diversified Healthcare Services Inc.</a></li>
<li><a href="http://www.drreddys.com">Doctor Reddys Laboratories Ltd.</a></li>
<li>Eon Labs</li>
<li><a href="http://www.frx.com">Forest Laboratories Inc.</a></li>
<li><a href="http://www.forestpharm.com">Forest Pharmaceuticals</a></li>
<li><a href="http://www.glenmark-generics.com">Glenmark Generics Ltd.</a></li>
<li><a href="http://www.greenstonellc.com">Greenstone LLC</a></li>
<li>Heartland Repack Services LLC</li>
<li><a href="http://www.innoviantpharmacy.com">Innoviant Pharmacy Inc.</a></li>
<li>International Laboratories Inc.</li>
<li><a href="http://www.invagen.com">InvaGen Pharmaceuticals Inc.</a></li>
<li><a href="http://www.inwoodlabs.com">Inwood Labs</a></li>
<li>Kali Laboratories Inc.</li>
<li>Lake Erie Medical and Surgical Supply</li>
<li><a href="http://www.legacypackaging.com">Legacy Pharmaceuticals Packaging LLC</a></li>
<li><a href="http://www.lundbeckinc.com">Lundbeck Inc.</a></li>
<li><a href="http://www.majorpharmaceuticals.com">Major Pharmaceuticals</a></li>
<li><a href="http://www.matrixlabsindia.com">Matrix Laboratories Ltd.</a></li>
<li><a href="http://www.medvantx.com">Medvantx Inc.</a></li>
<li><a href="http://www.unitdosesupply.com">Murfreesboro Pharmaceutical Nursing Supply</a></li>
<li><a href="http://www.mylan.com">Mylan</a></li>
<li><a href="http://www.nucarerx.com">Nucare Pharmaceuticals Inc.</a></li>
<li><a href="http://www.palmettopharm.com">Palmetto Pharmaceuticals Inc.</a></li>
<li><a href="http://www.pdrx.com">PD-Rx Pharmaceuticals Inc.</a></li>
<li><a href="http://www.perrigo.com">Perrigo Co.</a></li>
<li><a href="http://www.physicianstotalcare.com">Physicians Total Care Inc.</a></li>
<li><a href="http://www.pliva.com">Pliva Inc.</a></li>
<li><a href="http://www.preferredpharmaceuticals.com">Preferred Pharmaceuticals Inc.</a></li>
<li>Prepackage Specialists</li>
<li><a href="http://www.prepaksys.com">Prepak Systems Inc.</a></li>
<li><a href="http://www.rebelrx.com">Rebel Distributors Corp.</a></li>
<li><a href="http://www.remedyrepack.com">Remedy Repack</a></li>
<li>Resource Optimization and Innovation LLC</li>
<li><a href="http://www.roxane.com">Roxane Labs</a></li>
<li><a href="http://www.silarx.com">Silarx Pharmaceuticals</a></li>
<li><a href="http://www.southwoodhealthcare.com">Southwood Pharmaceuticals</a></li>
<li><a href="http://statrxusa.exporterus.com">Stat Rx Usa</a></li>
<li><a href="http://www.tevapharm.com">Teva Pharmaceutical Industries Ltd.</a></li>
<li><a href="http://www.torrentpharma.com">Torrent Pharmaceuticals</a></li>
<li>Va Cmop Dallas</li>
<li>Vangard Labs Inc.</li>
<li>W and D Distributing Co.</li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Solution</td><td>Oral</td><td>10 mg/5 ml</td></tr><tr><td>Tablet</td><td>Oral</td><td>10 mg, 20 mg, 40 mg</td></tr></tbody></table></td></tr><tr><th>Prices</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="prices"><thead><tr><th>Unit description</th><th>Cost</th><th>Unit</th></tr></thead><tbody><tr><td>Citalopram Hydrobromide 10 mg/5ml Solution 240ml Bottle</td><td>122.28USD</td><td>bottle</td></tr><tr><td>Celexa 40 mg tablet</td><td>3.88USD</td><td>tablet</td></tr><tr><td>Celexa 20 mg tablet</td><td>3.72USD</td><td>tablet</td></tr><tr><td>Celexa 10 mg tablet</td><td>3.57USD</td><td>tablet</td></tr><tr><td>Citalopram Hydrobromide 40 mg tablet</td><td>2.89USD</td><td>tablet</td></tr><tr><td>Citalopram Hydrobromide 20 mg tablet</td><td>2.8USD</td><td>tablet</td></tr><tr><td>Citalopram Hydrobromide 10 mg tablet</td><td>2.68USD</td><td>tablet</td></tr><tr><td>Citalopram hbr 40 mg tablet</td><td>2.53USD</td><td>tablet</td></tr><tr><td>Citalopram hbr 20 mg tablet</td><td>2.43USD</td><td>tablet</td></tr><tr><td>Citalopram hbr 10 mg tablet</td><td>2.33USD</td><td>tablet</td></tr><tr><td>Celexa 20 mg Tablet</td><td>1.47USD</td><td>tablet</td></tr><tr><td>Celexa 40 mg Tablet</td><td>1.47USD</td><td>tablet</td></tr><tr><td>Ctp 30 30 mg Tablet</td><td>0.99USD</td><td>tablet</td></tr><tr><td>Apo-Citalopram 20 mg Tablet</td><td>0.82USD</td><td>tablet</td></tr><tr><td>Apo-Citalopram 40 mg Tablet</td><td>0.82USD</td><td>tablet</td></tr><tr><td>Citalopram 20 mg Tablet</td><td>0.82USD</td><td>tablet</td></tr><tr><td>Citalopram 40 mg Tablet</td><td>0.82USD</td><td>tablet</td></tr><tr><td>Citalopram-Odan 20 mg Tablet</td><td>0.82USD</td><td>tablet</td></tr><tr><td>Citalopram-Odan 40 mg Tablet</td><td>0.82USD</td><td>tablet</td></tr><tr><td>Co Citalopram 20 mg Tablet</td><td>0.82USD</td><td>tablet</td></tr><tr><td>Co Citalopram 40 mg Tablet</td><td>0.82USD</td><td>tablet</td></tr><tr><td>Jamp-Citalopram 20 mg Tablet</td><td>0.82USD</td><td>tablet</td></tr><tr><td>Jamp-Citalopram 40 mg Tablet</td><td>0.82USD</td><td>tablet</td></tr><tr><td>Mint-Citalopram 20 mg Tablet</td><td>0.82USD</td><td>tablet</td></tr><tr><td>Mint-Citalopram 40 mg Tablet</td><td>0.82USD</td><td>tablet</td></tr><tr><td>Mylan-Citalopram 20 mg Tablet</td><td>0.82USD</td><td>tablet</td></tr><tr><td>Mylan-Citalopram 40 mg Tablet</td><td>0.82USD</td><td>tablet</td></tr><tr><td>Ng Citalopram 20 mg Tablet</td><td>0.82USD</td><td>tablet</td></tr><tr><td>Ng Citalopram 40 mg Tablet</td><td>0.82USD</td><td>tablet</td></tr><tr><td>Novo-Citalopram 20 mg Tablet</td><td>0.82USD</td><td>tablet</td></tr><tr><td>Novo-Citalopram 40 mg Tablet</td><td>0.82USD</td><td>tablet</td></tr><tr><td>Phl-Citalopram 20 mg Tablet</td><td>0.82USD</td><td>tablet</td></tr><tr><td>Phl-Citalopram 40 mg Tablet</td><td>0.82USD</td><td>tablet</td></tr><tr><td>Pms-Citalopram 20 mg Tablet</td><td>0.82USD</td><td>tablet</td></tr><tr><td>Pms-Citalopram 40 mg Tablet</td><td>0.82USD</td><td>tablet</td></tr><tr><td>Ran-Citalo 20 mg Tablet</td><td>0.82USD</td><td>tablet</td></tr><tr><td>Ran-Citalo 40 mg Tablet</td><td>0.82USD</td><td>tablet</td></tr><tr><td>Ran-Citalopram 20 mg Tablet</td><td>0.82USD</td><td>tablet</td></tr><tr><td>Ran-Citalopram 40 mg Tablet</td><td>0.82USD</td><td>tablet</td></tr><tr><td>Ratio-Citalopram 20 mg Tablet</td><td>0.82USD</td><td>tablet</td></tr><tr><td>Ratio-Citalopram 40 mg Tablet</td><td>0.82USD</td><td>tablet</td></tr><tr><td>Sandoz Citalopram 20 mg Tablet</td><td>0.82USD</td><td>tablet</td></tr><tr><td>Sandoz Citalopram 40 mg Tablet</td><td>0.82USD</td><td>tablet</td></tr><tr><td>Pms-Citalopram 10 mg Tablet</td><td>0.47USD</td><td>tablet</td></tr></tbody></table><div class="alert alert-warning clearfix">DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.</div></td></tr><tr><th>Patents</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="patents"><thead><tr><th>Country</th><th>Patent Number</th><th>Approved</th><th>Expires (estimated)</th></tr></thead><tbody><tr><td>Canada</td><td>2353693</td><td>2003-07-22</td><td>2021-07-24</td></tr><tr><td>Canada</td><td>2049368</td><td>2001-10-23</td><td>2011-08-16</td></tr></tbody></table></td></tr><tr id="properties"><th class="divider" colspan="2">Properties</th></tr><tr><th>State</th><td>solid</td></tr><tr><th>Experimental Properties</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><tr><th class="head-medium">Property</th><th class="head-large">Value</th><th>Source</th></tr><tr><td>melting point</td><td>182-183 &#176;C</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>water solubility</td><td>Sparingly soluble </td><td>FDA label </td></tr><tr><td>logP</td><td>3.5</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></table></td></tr><tr><th>Predicted Properties</th><td class="data-table-container"><table class="table table-condensed table-striped"><thead><tr><th class="head-medium">Property</th><th class="head-large">Value</th><th>Source</th></tr></thead><tbody><tr><td>water solubility</td><td>5.88e-03 g/l</td><td><a href="http://www.vcclab.org/lab/alogps/" target="_blank">ALOGPS</a></td></tr><tr><td>logP</td><td>3.58</td><td><a href="http://www.vcclab.org/lab/alogps/" target="_blank">ALOGPS</a></td></tr><tr><td>logP</td><td>3.76</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#logp_logd">ChemAxon</a></td></tr><tr><td>logS</td><td>-4.7</td><td><a href="http://www.vcclab.org/lab/alogps/" target="_blank">ALOGPS</a></td></tr><tr><td>pKa (strongest basic)</td><td>9.78</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#pka">ChemAxon</a></td></tr><tr><td>physiological charge</td><td>1</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#pka">ChemAxon</a></td></tr><tr><td>hydrogen acceptor count</td><td>3</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#h_bond">ChemAxon</a></td></tr><tr><td>hydrogen donor count</td><td>0</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#h_bond">ChemAxon</a></td></tr><tr><td>polar surface area</td><td>36.26</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#topolgical_surface">ChemAxon</a></td></tr><tr><td>rotatable bond count</td><td>5</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#topology_analysis">ChemAxon</a></td></tr><tr><td>refractivity</td><td>94.02</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#refractivity">ChemAxon</a></td></tr><tr><td>polarizability</td><td>35.4</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>number of rings</td><td>3</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#topology_analysis">ChemAxon</a></td></tr><tr><td>bioavailability</td><td>1</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>rule of five</td><td>Yes</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>Ghose filter</td><td>Yes</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>Veber's rule</td><td>Yes</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>MDDR-like rule</td><td>No</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><ul><li><a data-no-turbolink="true" href="/spectra/spectra/nmr_one_d/2022">1H NMR Spectrum</a></li>
<li><a data-no-turbolink="true" href="/spectra/spectra/nmr_two_d/1957">[1H,13C] 2D NMR Spectrum</a></li></ul></td></tr><tr id="references"><th class="divider" colspan="2">References</th></tr><tr><th>Synthesis Reference</th><td><span class="citations"><p>Hans Petersen, &#8220;Method for the preparation of citalopram.&#8221; U.S. Patent US6229026, issued December, 1992.</p></span><a class="wishart-link-out" href="https://www.google.com/?tbm=pts#q=6229026&amp;tbm=pts" target="_blank">US6229026 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><th>General Reference</th><td><span class="citations"><ol>
	<li>Sindrup SH, Bjerre U, Dejgaard A, Brosen K, Aaes-Jorgensen T, Gram LF: The selective serotonin reuptake inhibitor citalopram relieves the symptoms of diabetic neuropathy. Clin Pharmacol Ther. 1992 Nov;52(5):547-52. <a href="http://www.ncbi.nlm.nih.gov/pubmed/1424428">Pubmed</a></li>
	<li>Atmaca M, Kuloglu M, Tezcan E, Semercioz A: The efficacy of citalopram in the treatment of premature ejaculation: a placebo-controlled study. Int J Impot Res. 2002 Dec;14(6):502-5. <a href="http://www.ncbi.nlm.nih.gov/pubmed/12494286">Pubmed</a></li>
	<li>Andersen G, Vestergaard K, Riis JO: Citalopram for post-stroke pathological crying. Lancet. 1993 Oct 2;342(8875):837-9. <a href="http://www.ncbi.nlm.nih.gov/pubmed/8104273">Pubmed</a></li>
	<li>Clayton A, Keller A, McGarvey EL: Burden of phase-specific sexual dysfunction with SSRIs. J Affect Disord. 2006 Mar;91(1):27-32. Epub 2006 Jan 20. <a href="http://www.ncbi.nlm.nih.gov/pubmed/16430968">Pubmed</a></li>
	<li>Baumann P: Pharmacology and pharmacokinetics of citalopram and other SSRIs. Int Clin Psychopharmacol. 1996 Mar;11 Suppl 1:5-11. <a href="http://www.ncbi.nlm.nih.gov/pubmed/8732438">Pubmed</a></li>
	<li><span class="caps">FDA</span> label</li>
	<li>Hyttel J, Bogeso KP, Perregaard J, Sanchez C: The pharmacological effect of citalopram residues in the (S)-(+)-enantiomer. J Neural Transm Gen Sect. 1992;88(2):157-60. <a href="http://www.ncbi.nlm.nih.gov/pubmed/1632943">Pubmed</a></li>
	<li>Caccia S: Metabolism of the newer antidepressants. An overview of the pharmacological and pharmacokinetic implications. Clin Pharmacokinet. 1998 Apr;34(4):281-302. <a href="http://www.ncbi.nlm.nih.gov/pubmed/9571301">Pubmed</a></li>
</ol></span></td></tr><tr><th>External Links</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Resource</th><th>Link</th></tr></thead><tbody><tr><td>KEGG Drug</td><td><a class="wishart-link-out" href="http://www.genome.jp/dbget-bin/www_bget?drug:D07704" target="_blank">D07704 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>KEGG Compound</td><td><a class="wishart-link-out" href="http://www.genome.jp/dbget-bin/www_bget?cpd:C07572" target="_blank">C07572 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>PubChem Compound</td><td><a class="wishart-link-out" href="http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=2771" target="_blank">2771 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>PubChem Substance</td><td><a class="wishart-link-out" href="http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=46508746" target="_blank">46508746 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>ChemSpider</td><td><a class="wishart-link-out" href="http://www.chemspider.com/Chemical-Structure.2669.html" target="_blank">2669 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>BindingDB</td><td><a class="wishart-link-out" href="http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=25870" target="_blank">25870 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>ChEBI</td><td><a class="wishart-link-out" href="http://www.ebi.ac.uk/chebi/searchId.do?chebiId=3723" target="_blank">3723 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>ChEMBL</td><td><a class="wishart-link-out" href="http://www.ebi.ac.uk/chembldb/index.php/compound/inspect/CHEMBL549" target="_blank">CHEMBL549 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Therapeutic Targets Database</td><td><a class="wishart-link-out" href="http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DAP000118" target="_blank">DAP000118 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>PharmGKB</td><td><a class="wishart-link-out" href="http://www.pharmgkb.org/drug/PA449015" target="_blank">PA449015 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Drug Product Database</td><td><a class="wishart-link-out" href="http://205.193.93.51/dpdonline/searchRequest.do?din=2248051" target="_blank">2248051 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>RxList</td><td><a class="wishart-link-out" href="http://www.rxlist.com/cgi/generic/citalo.htm" target="_blank">http://www.rxlist.com/cgi/generic/citalo.htm <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Drugs.com</td><td><a class="wishart-link-out" href="http://www.drugs.com/citalopram.html" target="_blank">http://www.drugs.com/citalopram.html <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Wikipedia</td><td><a class="wishart-link-out" href="http://en.wikipedia.org/wiki/Citalopram" target="_blank">Citalopram <span class="glyphicon glyphicon-new-window"> </span></a></td></tr></tbody></table></td></tr><tr><th>ATC Codes</th><td>N06AB04<ul class="atc-drug-tree"><li><a href="/atc/N#N">N &#8212; NERVOUS SYSTEM</a></li><li><a href="/atc/N06#N06">N06 &#8212; PSYCHOANALEPTICS</a></li><li><a href="/atc/N06A#N06A">N06A &#8212; ANTIDEPRESSANTS</a></li><li><a href="/atc/N06AB#N06AB">N06AB &#8212; Selective serotonin reuptake inhibitors</a></li></ul>N06AB10<ul class="atc-drug-tree"><li><a href="/atc/N#N">N &#8212; NERVOUS SYSTEM</a></li><li><a href="/atc/N06#N06">N06 &#8212; PSYCHOANALEPTICS</a></li><li><a href="/atc/N06A#N06A">N06A &#8212; ANTIDEPRESSANTS</a></li><li><a href="/atc/N06AB#N06AB">N06AB &#8212; Selective serotonin reuptake inhibitors</a></li></ul></td></tr><tr><th>AHFS Codes</th><td><ul><li>28:16.04.20</li></ul></td></tr><tr><th>PDB Entries</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>FDA label</th><td><a href="/system/fda_labels/DB00215.pdf?1265922805">show</a>(148 KB)</td></tr><tr><th>MSDS</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB01418">Acenocoumarol</a></td><td>The SSRI, citalopram, increases the effect of anticoagulant, acenocoumarol.</td></tr><tr><td><a href="/drugs/DB00918">Almotriptan</a></td><td>Increased risk of CNS adverse effects</td></tr><tr><td><a href="/drugs/DB01125">Anisindione</a></td><td>The SSRI, citalopram, increases the effect of anticoagulant, anisindione.</td></tr><tr><td><a href="/drugs/DB06697">Artemether</a></td><td>Additive QTc-prolongation may occur. Concomitant therapy should be avoided.</td></tr><tr><td><a href="/drugs/DB01136">Carvedilol</a></td><td>The SSRI, citalopram, may increase the bradycardic effect of the beta-blocker, carvedilol.</td></tr><tr><td><a href="/drugs/DB01211">Clarithromycin</a></td><td>Possible serotoninergic syndrome with this combination</td></tr><tr><td><a href="/drugs/DB00363">Clozapine</a></td><td>The antidepressant increases the effect of clozapine</td></tr><tr><td><a href="/drugs/DB06700">Desvenlafaxine</a></td><td>Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.</td></tr><tr><td><a href="/drugs/DB00266">Dicoumarol</a></td><td>The SSRI, citalopram, increases the effect of anticoagulant, dicumarol.</td></tr><tr><td><a href="/drugs/DB00216">Eletriptan</a></td><td>Increased risk of CNS adverse effects</td></tr><tr><td><a href="/drugs/DB00199">Erythromycin</a></td><td>Possible serotoninergic syndrome with this combination</td></tr><tr><td><a href="/drugs/DB06414">Etravirine</a></td><td>Citalopram, when used concomitantly with etravirine (a CYP2C19 inhibitor), may experience an increase in serum concentration. 

It is recommended to maintain the dose of citalopram below 20mg/day, and to monitor for toxicity. The symptoms which often accompany citalopram overdose are dizziness, sweating, nausea, vomiting, tremor, somnolence,sinus tachycardia,amnesia, confusion, coma, convulsions, hyperventilation, cyanosis, rhabdomyolysis, acute renal failure, and ECG changes (including QTc prolongation, nodal rhythm, ventricular arrhythmia, and torsade de pointes). </td></tr><tr><td><a href="/drugs/DB00998">Frovatriptan</a></td><td>Increased risk of CNS adverse effects</td></tr><tr><td><a href="/drugs/DB01381">Ginkgo biloba</a></td><td>Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided.</td></tr><tr><td><a href="/drugs/DB01247">Isocarboxazid</a></td><td>Possible severe adverse reaction with this combination</td></tr><tr><td><a href="/drugs/DB01321">Josamycin</a></td><td>Possible serotoninergic sydrome with this combination</td></tr><tr><td><a href="/drugs/DB01009">Ketoprofen</a></td><td>Concomitant therapy may result in additive antiplatelet effects and increase the risk of bleeding. Monitor for increased risk of bleeding during concomitant therapy. </td></tr><tr><td><a href="/drugs/DB00601">Linezolid</a></td><td>Combination associated with possible serotoninergic syndrome</td></tr><tr><td><a href="/drugs/DB06708">Lumefantrine</a></td><td>Additive QTc-prolongation may occur. Concomitant therapy should be avoided. </td></tr><tr><td><a href="/drugs/DB00264">Metoprolol</a></td><td>The SSRI, citalopram, may increase the bradycardic effect of the beta-blocker, metoprolol.</td></tr><tr><td><a href="/drugs/DB01171">Moclobemide</a></td><td>Possible serotoninergic syndrome</td></tr><tr><td><a href="/drugs/DB00952">Naratriptan</a></td><td>Increased risk of CNS adverse effects</td></tr><tr><td><a href="/drugs/DB00497">Oxycodone</a></td><td>Increased risk of serotonin syndrome</td></tr><tr><td><a href="/drugs/DB00780">Phenelzine</a></td><td>Possible severe adverse reaction with this combination</td></tr><tr><td><a href="/drugs/DB01100">Pimozide</a></td><td>The SSRI, citalopram, may increase the effect and toxicity of pimozide.</td></tr><tr><td><a href="/drugs/DB00571">Propranolol</a></td><td>The SSRI, citalopram, may increase the bradycardic effect of the beta-blocker, propranolol.</td></tr><tr><td><a href="/drugs/DB01367">Rasagiline</a></td><td>Possible severe adverse reaction with this combination</td></tr><tr><td><a href="/drugs/DB00953">Rizatriptan</a></td><td>Increased risk of CNS adverse effects</td></tr><tr><td><a href="/drugs/DB01037">Selegiline</a></td><td>Possible severe adverse reaction with this combination</td></tr><tr><td><a href="/drugs/DB01105">Sibutramine</a></td><td>Risk of serotoninergic syndrome </td></tr><tr><td><a href="/drugs/DB01323">St. John's Wort</a></td><td>St. John's Wort increases the effect and toxicity of the SSRI, citalopram.</td></tr><tr><td><a href="/drugs/DB00669">Sumatriptan</a></td><td>Increased risk of CNS adverse effects</td></tr><tr><td><a href="/drugs/DB00976">Telithromycin</a></td><td>Telithromycin may reduce clearance of Citalopram. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Citalopram if Telithromycin is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB01600">Tiaprofenic acid</a></td><td>Additive antiplatelet effects increase the risk of bleeding. Consider alternate therapy or monitor for increased bleeding. </td></tr><tr><td><a href="/drugs/DB00208">Ticlopidine</a></td><td>Ticlopidine may decrease the metabolism and clearance of Citalopram. Consider alternate therapy or monitor for adverse/toxic effects of Citalopram if Ticlopidine is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00500">Tolmetin</a></td><td>Increased antiplatelet effects may enhance the risk of bleeding. Alternate therapy may be considered or monitor for inreased bleeding during concomitant therapy. </td></tr><tr><td><a href="/drugs/DB00193">Tramadol</a></td><td>The use of two serotonin modulators, such as citalopram and tramadol, may increase the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy.</td></tr><tr><td><a href="/drugs/DB00752">Tranylcypromine</a></td><td>Increased risk of serotonin syndrome. Concomitant therapy should be avoided. A significant washout period, dependent on the half-lives of the agents, should be employed between therapies.</td></tr><tr><td><a href="/drugs/DB00656">Trazodone</a></td><td>Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.</td></tr><tr><td><a href="/drugs/DB00374">Treprostinil</a></td><td>The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the antiplatelet agent, Citalopram. Monitor for increased bleeding during concomitant thearpy. </td></tr><tr><td><a href="/drugs/DB00726">Trimipramine</a></td><td>The SSRI, Citalopram, may decrease the metabolism and clearance of Trimipramine. Increased risk of serotonin syndrome. Monitor for changes in Trimipramine efficacy and toxicity if Citalopram is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB00427">Triprolidine</a></td><td>The CNS depressants, Triprolidine and Citalopram, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. </td></tr><tr><td><a href="/drugs/DB01361">Troleandomycin</a></td><td>Possible serotoninergic syndrome with this combination</td></tr><tr><td><a href="/drugs/DB00285">Venlafaxine</a></td><td>Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.</td></tr><tr><td><a href="/drugs/DB00582">Voriconazole</a></td><td>Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of citalopram by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of citalopram if voriconazole is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00682">Warfarin</a></td><td>The SSRI, citalopram, increases the effect of anticoagulant, warfarin.</td></tr><tr><td><a href="/drugs/DB00246">Ziprasidone</a></td><td>Additive QTc-prolongation may occur increasing the risk of life-threatening ventricular arrhythmias and torsade de pointes. Concomitant therapy should be avoided. </td></tr><tr><td><a href="/drugs/DB00315">Zolmitriptan</a></td><td>The use of two serotonin modulators, such as zolmitriptan and citalopram, may increase the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy.</td></tr><tr><td><a href="/drugs/DB01624">Zuclopenthixol</a></td><td>Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).</td></tr><tr><td><a href="/drugs/DB08919">Zuclopenthixol acetate</a></td><td>Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).</td></tr><tr><td><a href="/drugs/DB08920">Zuclopenthixol decanoate</a></td><td>Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>Avoid alcohol.</li>
<li>Avoid St.John's Wort.</li>
<li>Take without regard to meals.</li></ul></td></tr></tbody></table>